Publications by authors named "E U Poluektova"
Article Synopsis
- The study focuses on how gut microbiota, particularly commensal bacteria like lactobacilli, interact with the host immune system's cytokines, which are critical in managing inflammation and gut health.
- Using next-generation RNA sequencing, researchers examined the transcriptional responses of lactobacillus strains K32 and R19-3 to various cytokines, revealing significant changes in gene expression linked to metabolism and stress response, especially upon exposure to IL-8 and IL-10.
- The findings highlight a complex adaptation mechanism where these bacteria adjust their gene expression in response to inflammatory signals, paving the way for potential probiotic therapies for conditions like inflammatory bowel disease (IBD).
The aim of this study was to investigate the levels of various tryptophan metabolites in patients with alcoholic liver disease (ALD) and metabolic-associated fatty liver disease (MAFLD) at different stages of the disease. The present study included 44 patients diagnosed with MAFLD, 40 patients diagnosed with ALD, and 14 healthy individuals in the control group. The levels of tryptophan and its 16 metabolites (3-OH anthranilic acid, 5-hydroxytryptophan, 5-methoxytryptamine, 6-hydroxymelatonin, indole-3-acetic acid, indole-3-butyric, indole-3-carboxaldehyde, indole-3-lactic acid, indole-3-propionic acid, kynurenic acid, kynurenine, melatonin, quinolinic acid, serotonin, tryptamine, and xanthurenic acid) in the serum were determined via high-performance liquid chromatography and tandem mass spectrometry.
View Article and Find Full Text PDFBackground: Sarcopenia and gut dysbiosis are common in cirrhosis. The aim is to study the correlations between the gut microbiota taxa and muscle mass level in cirrhosis.
Methods: The study included 40 cirrhosis patients including 18 patients with sarcopenia.
We aimed to systematize the results of published studies on the use of (SB) for the treatment of various liver disorders (CRD42022378050). Searches were conducted using PubMed and Scopus on 1 August 2022. The PubMed search was updated on 15 June 2024.
View Article and Find Full Text PDFArticle Synopsis
- The U-21 strain secretes chaperones, like the ClpL protein, which shows potential as a disaggregase for treating Parkinson's disease.
- Analysis of the C0965_000195 gene reveals that ClpL can assist in refolding misfolded proteins, particularly luciferases, helping cells manage protein damage.
- Experiments indicate that both the secreted culture medium from U-21 and purified ClpL can protect proteins from denaturation, suggesting ClpL's key role in the strain’s potential therapeutic benefits.